
Core Viewpoint - A class action securities lawsuit has been filed against Alto Neuroscience, Inc. due to alleged securities fraud affecting investors who purchased shares during its initial public offering and subsequent period [1][2]. Class Definition - The lawsuit aims to recover losses for investors who acquired Alto common stock through the Offering Documents related to the IPO on February 2, 2024, or purchased securities between February 2, 2024, and October 22, 2024 [2]. Case Details - The complaint alleges that the defendants made false statements regarding the effectiveness of the product pipeline, ALTO-100, in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects, as well as the overall business and financial outlook of Alto Neuroscience [3]. Next Steps - Investors who suffered losses during the specified timeframe have until September 19, 2025, to request appointment as lead plaintiff, with no costs or obligations to participate in the lawsuit [4]. Why Levi & Korsinsky - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders and consistently ranking among the top securities litigation firms in the United States [5].